Hong Kong IT Stock News

Innovent Biologics (SEHK:1801) has caught investor attention after dosing the first participant in its pivotal Phase 3 HeriCare-Breast01 trial for IBI354, a HER2-directed antibody drug conjugate in breast cancer. See our latest analysis for Innovent Biologics. That Phase 3 milestone comes on the back of an eventful few weeks, including a new collaboration with Eli Lilly and strong 2025 product revenue figures. The share price has a year to date return of 13.07% alongside a 1 year total...

Shougang Fushan Resources Group (SEHK:639) issued 2025 earnings guidance, flagging profit of HK$600 million to HK$700 million, compared with HK$1,494 million in 2024, as lower clean coking coal prices weigh on results. See our latest analysis for Shougang Fushan Resources Group. The earnings guidance lands after a strong run for investors, with the latest share price at HK$3.34 and a 1 year total shareholder return of 53.95% alongside a 5 year total shareholder return of 194.16%. This...

Bright Smart Securities & Commodities Group (SEHK:1428) is set to join the Hang Seng Composite Index, with the change effective March 9, 2026. This inclusion also paves the way for Shanghai Hong Kong Stock Connect eligibility. See our latest analysis for Bright Smart Securities & Commodities Group. The upcoming index inclusion sits on top of a strong run, with a 90 day share price return of 25% and a 1 year total shareholder return of 247.33% pointing to building momentum rather than fading...

Alcohol partnership with Songhe puts Guoquan Food’s beverage plans in focus Guoquan Food (Shanghai) (SEHK:2517) has signed an alcoholic beverage procurement agreement with Songhe Group, tying drinks more tightly to its hot pot and barbecue offerings across more than 11,000 retail stores. See our latest analysis for Guoquan Food (Shanghai). The new alcohol deal lands after a strong 1 year total shareholder return of 119.77%, even though recent momentum has softened. The 7 day share price...

FDA clearance puts CS2009 in focus for CStone investors CStone Pharmaceuticals (SEHK:2616) said the U.S. FDA has cleared its IND for a Phase II trial of immunotherapy candidate CS2009 in advanced solid tumors, expanding an ongoing global multicenter study. See our latest analysis for CStone Pharmaceuticals. The FDA clearance comes as CStone’s share price sits at HK$5.91, with a 7 day share price return of 14.98% and a 1 year total shareholder return of 113.36%. This suggests momentum has...

SSY Group (SEHK:2005) has issued preliminary 2025 earnings guidance, telling investors to expect a 45% to 60% reduction in profit attributable to equity shareholders compared with the HK$1,061,150,000 reported for 2024. See our latest analysis for SSY Group. At a share price of HK$3.02, SSY Group has a modest 1-day share price return of a 0.33% decline, while its year-to-date share price return of 5.59% contrasts with a 3-year total shareholder return of a 28.75% decline. This suggests that...

China Medical System Holdings (SEHK:867) has drawn fresh attention after Chinese regulators cleared human trials for its CMS-D017 kidney disease therapy, alongside a new AI-focused drug discovery partnership with Insilico Medicine. See our latest analysis for China Medical System Holdings. The recent CMS D017 trial clearance and AI drug discovery tie up come as China Medical System Holdings’ share price sits at HK$15.33, with a 30 day share price return of 9.34% and a 1 year total shareholder...

Why Shanghai Henlius Biotech Is On Investors’ Radar Shanghai Henlius Biotech (SEHK:2696) has recently caught investor attention, with the share price moving over the past week, month and past 3 months, prompting a closer look at its fundamentals and returns. See our latest analysis for Shanghai Henlius Biotech. At the current share price of HK$70.5, Henlius has shown firm momentum, with a 10.5% 90 day share price return and a very large 1 year total shareholder return. Together, these figures...

InnoCare Pharma (SEHK:9969) has drawn fresh attention after dosing the first patient in a Phase II/III trial of its TYK2 inhibitor soficitinib for chronic spontaneous urticaria, alongside progress across several other dermatology indications. See our latest analysis for InnoCare Pharma. Despite the steady stream of trial updates and the recent IND approval for ICP-538, InnoCare Pharma’s 90 day share price return decline of 14.51% contrasts with a 1 year total shareholder return of 91.23%,...

What recent performance data suggests about AIA Group (SEHK:1299) AIA Group (SEHK:1299) has drawn investor attention after a 1 day return of 2.55%, alongside a 1 year total return of 53.15% and a 3 year total return of 6.65%. See our latest analysis for AIA Group. That 2.55% 1 day share price return sits against a 7 day share price decline of 4.63% and a 90 day share price gain of 4.84%. The 1 year total shareholder return of 53.15% contrasts with a 5 year total shareholder return decline of...

Why Dmall’s recent share performance is catching attention Dmall (SEHK:2586) has attracted fresh interest after a strong run in its share price, with returns of 9.9% over the past month and 11.8% over the past 3 months. See our latest analysis for Dmall. Zooming out, Dmall’s 20.64% year to date share price return and 41.07% total shareholder return over the past year point to building momentum around its HK$9.0 share price, as investors reassess its growth prospects and risks. If this kind of...

Why Chery Automobile Is Drawing Investor Attention Now Chery Automobile (SEHK:9973) has caught investor interest recently, with the share price around HK$28.68 and short term returns mixed across the past week, month, and past 3 months. See our latest analysis for Chery Automobile. Stepping back from the daily moves, Chery Automobile’s share price return has been slightly positive over the past week but softer over the past quarter and year to date. This hints that earlier momentum has cooled...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Hengan International Group fair value estimate is HK$34.85...

If you are wondering whether Tencent Holdings is attractively priced today or already reflects most of its potential, this article will walk you through how its current share price stacks up against several valuation checks. Tencent's share price last closed at HK$532.0, with a 2.8% decline over 7 days, a 13.8% decline over 30 days and a 14.6% decline year to date, while the 1 year return sits at 13.0% and the 3 year return at 45.8%, compared to a 19.6% decline over 5 years. Recent headlines...

As global markets navigate the complexities of AI disruption and economic shifts, Asian stocks have shown resilience, with indices like Japan's Nikkei 225 experiencing notable gains. In this environment, identifying undervalued stocks requires a keen eye for companies that demonstrate strong fundamentals and potential for growth amidst changing market conditions.

Lenovo Group recently reported third-quarter 2025/26 results showing record sales of US$22,204.33 million, alongside lower quarterly net income of US$545.54 million, while nine‑month profits edged higher year on year to US$1.39 billion. At the same time, Lenovo highlighted rapid growth in AI‑related revenue, restructured its Infrastructure Solutions Group for long-term AI opportunities, and launched new ThinkSmart–Huddly meeting solutions to deepen its presence in AI‑enabled...

The Meitu, Inc. ( HKG:1357 ) share price has fared very poorly over the last month, falling by a substantial 30...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

China National Building Material Company Limited ( HKG:3323 ) shares have had a really impressive month, gaining 27...

The Honworld Group Limited ( HKG:2226 ) share price has fared very poorly over the last month, falling by a substantial...

The Bank of East Asia, Limited ( HKG:23 ) is reducing its dividend from last year's comparable payment to HK$0.22 on...

To the annoyance of some shareholders, TI Cloud Inc. ( HKG:2167 ) shares are down a considerable 28% in the last month...

Despite an already strong run, TBK & Sons Holdings Limited ( HKG:1960 ) shares have been powering on, with a gain of...

With a price-to-earnings (or "P/E") ratio of 22.7x Kingsoft Corporation Limited ( HKG:3888 ) may be sending very...